We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > PhIII

News List

Novartis' melanoma combo fails in PhIII pharmatimes
August 24, 2020
Novartis has announced that its investigational immunotherapy spartalizumab in combination with Tafinlar (dabrafenib) and Mekinist (trametinib) failed to improve progression-free survival in patients with advanced melanoma.
Breztri Aerosphere cut rate of COPD exacerbations in PhIII trial pharmatimes
June 30, 2020
AstraZeneca’s triple-combination therapy Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) significantly cut the rate of moderate or severe exacerbations compared with two dual-combination therapies in patients with ...
Sanofi, Alnylam’s RNAi therapeutic smashes PhIII targets pharmatimes
September 22, 2017
An investigational RNAi therapeutic being developed by Sanofi Genzyme and Alnylam Pharmaceuticals has hit targets in a late stage trial involving patients with hereditary ATTR amyloidosis with polyneuropathy.